Trial Profile
TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 May 2016 New trial record